ATE464909T1 - Humane anti-chemokinrezeptoren igm antikörper - Google Patents

Humane anti-chemokinrezeptoren igm antikörper

Info

Publication number
ATE464909T1
ATE464909T1 AT00978542T AT00978542T ATE464909T1 AT E464909 T1 ATE464909 T1 AT E464909T1 AT 00978542 T AT00978542 T AT 00978542T AT 00978542 T AT00978542 T AT 00978542T AT E464909 T1 ATE464909 T1 AT E464909T1
Authority
AT
Austria
Prior art keywords
hiv
receptors
human anti
chemokine receptors
igm antibodies
Prior art date
Application number
AT00978542T
Other languages
German (de)
English (en)
Inventor
Peter I Lobo
Original Assignee
Peter I Lobo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter I Lobo filed Critical Peter I Lobo
Application granted granted Critical
Publication of ATE464909T1 publication Critical patent/ATE464909T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
AT00978542T 1999-11-15 2000-11-14 Humane anti-chemokinrezeptoren igm antikörper ATE464909T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43969099A 1999-11-15 1999-11-15
US09/684,813 US6610834B1 (en) 1998-11-18 2000-10-10 Human IgM antibodies to chemokine receptors
PCT/US2000/031051 WO2001035980A1 (en) 1999-11-14 2000-11-14 HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS

Publications (1)

Publication Number Publication Date
ATE464909T1 true ATE464909T1 (de) 2010-05-15

Family

ID=27032133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978542T ATE464909T1 (de) 1999-11-15 2000-11-14 Humane anti-chemokinrezeptoren igm antikörper

Country Status (8)

Country Link
US (1) US6610834B1 (enExample)
EP (1) EP1231930B1 (enExample)
JP (1) JP2003516940A (enExample)
AT (1) ATE464909T1 (enExample)
AU (1) AU1599601A (enExample)
CA (1) CA2389851A1 (enExample)
DE (1) DE60044259D1 (enExample)
WO (1) WO2001035980A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
US20080118522A1 (en) * 1998-11-18 2008-05-22 Lobo Peter I Naturally occuring IgM antibodies that bind lymphocytes
WO2005108989A2 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
EP1817054A1 (en) * 2004-12-01 2007-08-15 Peter I. Lobo Naturally occuring igm antibodies that bind lymphocytes
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
BRPI0707446A2 (pt) 2006-02-02 2011-05-03 Allergan Inc composições e métodos para o tratamento de doença oftálmica
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008019817A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20210311048A1 (en) * 2016-02-16 2021-10-07 Celltrend Gmbh Anti-CXC chemokine receptor antibodies and C-X-C chemokines for the diagnosis of autoimmune disease and graft-versus-host disease
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
EP0672142B1 (en) * 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
WO1997049424A1 (en) * 1996-06-25 1997-12-31 The Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JP2000229997A (ja) * 1999-02-10 2000-08-22 Nissui Pharm Co Ltd 環状ペプチド及びエイズワクチン

Also Published As

Publication number Publication date
CA2389851A1 (en) 2001-05-25
EP1231930A4 (en) 2005-07-27
JP2003516940A (ja) 2003-05-20
EP1231930A1 (en) 2002-08-21
AU1599601A (en) 2001-05-30
US6610834B1 (en) 2003-08-26
EP1231930B1 (en) 2010-04-21
DE60044259D1 (de) 2010-06-02
WO2001035980A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
Melenotte et al. Immune responses during COVID-19 infection
Karlsson et al. The known unknowns of T cell immunity to COVID-19
ATE464909T1 (de) Humane anti-chemokinrezeptoren igm antikörper
Lopalco et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro
Clerici et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41
Kohler et al. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination
Sandberg et al. SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
Melchers et al. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses
Hosie et al. A monoclonal antibody which blocks infection with feline immunodeficiency virus identifies a possible non-CD4 receptor
Klasse et al. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
Laska et al. Human endogenous retroviral genetic element with immunosuppressive activity in both human autoimmune diseases and experimental arthritis
Kulkarni et al. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of envelope and a region from Tat protein
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Greczmiel et al. LCMV‐specific CD4 T cell dependent polyclonal B‐cell activation upon persistent viral infection is short lived and extrafollicular
Motsoeneng et al. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
Florio et al. The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils
Benlarbi et al. CD4 T cell counts are inversely correlated with anti-cluster A antibodies in antiretroviral therapy-treated PLWH
Hirbod et al. HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals
Brown et al. The conserved carboxy terminal region of HIV-1 gp120 is recognized by seronegative HIV-exposed people
Sattentau et al. New templates for HIV-1 antibody-based vaccine design
Ahmed et al. Role of CD8+ cell‐produced anti‐viral factors in protective immunity in HIV‐2‐exposed but seronegative macaques resistant to intrarectal SIVsm challenge
Pahar et al. Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques
Koshino et al. Detection of Antibodies to HN-1 gp41-and HIA Class II Antigen-derived Peptides in SLE Patients
Leinert et al. Microbial translocation in simian immunodeficiency virus (SIV)‐infected rhesus monkeys (Macaca mulatta)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties